October 16, 2023
microMESH is developing a proprietary technology for the controlled, sustained, and deep intratumor delivery of small molecules, antibodies, and RNA-based medicines. The technology, called also microMESH, is a flexible biodegradable polymeric foil that adheres to the malignant tissue and locally deploys complex combination therapies. microMESH focuses on the treatment of glioblastoma and brain tumors, which continue to be the less curable forms of any cancer. microMESH is a platform technology that could be readily applied to the treatment of other cancers, and possibly non oncological disorders. microMESH relies on an interdisciplinary team of engineers, biotechnologists, and neurosurgeons. Success will result in a clinically validated microMESH for the treatment of newly diagnosed and recurrent brain tumors via chemo-immuno therapy.
SPARK at Stanford